{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:45:59Z","timestamp":1758638759032},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,11]],"date-time":"2016-03-11T00:00:00Z","timestamp":1457654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["contraceptionjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.contraception.2016.03.003","type":"journal-article","created":{"date-parts":[[2016,3,11]],"date-time":"2016-03-11T01:47:09Z","timestamp":1457660829000},"page":"40-47","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial"],"prefix":"10.1016","volume":"94","author":[{"given":"Kavita","family":"Nanda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Callahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kawango","family":"Agot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lut","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laneta","family":"Dorflinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2016.03.003_bb0005","series-title":"Population Division (2013). World Contraceptive Patterns","author":"United Nations","year":"2013"},{"key":"10.1016\/j.contraception.2016.03.003_bb0010","series-title":"National, regional and global estimates and projections of the number of women aged 15 to 49 who are married or in a union, 1970\u20132030","author":"Kantorova","year":"2013"},{"key":"10.1016\/j.contraception.2016.03.003_bb0015","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.contraception.2010.08.013","article-title":"Provision of DMPA by community health workers: what the evidence shows","volume":"83","author":"Malarcher","year":"2011","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2016.03.003_bb0020","series-title":"Expanding services for injectables. population reports, series K","author":"Land","year":"2006"},{"key":"10.1016\/j.contraception.2016.03.003_bb0025","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"Van Damme","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.contraception.2016.03.003_bb0030","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/QAI.0b013e3182794723","article-title":"Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence?","volume":"62","author":"Adams","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.contraception.2016.03.003_bb0035","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/QAI.0000000000000158","article-title":"FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis","volume":"66","author":"Corneli","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.contraception.2016.03.003_bb0040","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1210\/jcem-44-1-32","article-title":"Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA","volume":"44","author":"Ortiz","year":"1977","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.contraception.2016.03.003_bb0045","first-page":"381","article-title":"Pharmacokinetics of depot medroxyprogesterone acetate contraception","volume":"41","author":"Mishell","year":"1996","journal-title":"J Reprod Med"},{"key":"10.1016\/j.contraception.2016.03.003_bb0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.contraception.2003.09.005","article-title":"Serum medroxyprogesterone acetate levels in new and repeat users of depot medroxyprogesterone acetate at the end of the dosing interval","volume":"69","author":"Smit","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2016.03.003_bb0055","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0010-7824(74)90130-9","article-title":"Return of ovulatory cyclicity following an intramuscular injection of medroxyprogesterone acetate (Provera)","volume":"10","author":"Kirton","year":"1974","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2016.03.003_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0010-7824(79)90038-6","article-title":"Blood levels of medroxyprogesterone acetate after multiple injections of depoprovera or cycloprovera","volume":"20","author":"Koetsawang","year":"1979","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2016.03.003_bb0065","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/00016347709158338","article-title":"Endometrial histology and circulating levels of medroxyprogesterone acetate (MPA), estradiol, FSH and LH in women with MPA induced amenorrhoea compared with women with secondary amenorrhoea","volume":"56","author":"Jeppsson","year":"1977","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.contraception.2016.03.003_bb0070","series-title":"Note for guidance on the investigation of bioavailability and bioequivalence","author":"Agency","year":"2000"},{"key":"10.1016\/j.contraception.2016.03.003_bb0075","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.contraception.2013.07.002","article-title":"Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm","volume":"89","author":"Halpern","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2016.03.003_bb0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.contraception.2004.01.011","article-title":"Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera","volume":"70","author":"Jain","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2016.03.003_bb0085","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.clinthera.2004.11.013","article-title":"Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104mg\/0.65mL) contraceptive formulation in Asian women","volume":"26","author":"Toh","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.contraception.2016.03.003_bb0090","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1592\/phco.29.8.924","article-title":"Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives","volume":"29","author":"Kearney","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.contraception.2016.03.003_bb0095","first-page":"7","article-title":"Pharmacokinetics of injectable contraceptives","volume":"5","author":"Josue Garza Flores","year":"2000","journal-title":"Gynaecol Forum"},{"key":"10.1016\/j.contraception.2016.03.003_bb0100","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.contraception.2010.01.021","article-title":"Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously","volume":"81","author":"Segall-Gutierrez","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2016.03.003_bb0105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0010-7824(82)90171-8","article-title":"Metabolism of injectable formulations of contraceptive steroids in obese and thin women","volume":"26","author":"Fotherby","year":"1982","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2016.03.003_bb0110","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0010-7824(99)00081-5","article-title":"Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): assessment of return of ovulation after three monthly injections in surgically sterile women","volume":"60","author":"Rahimy","year":"1999","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2016.03.003_bb0115","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/1479-7364-5-4-265","article-title":"Analysis of pharmacogenetic traits in two distinct south African populations","volume":"5","author":"Ikediobi","year":"2011","journal-title":"Hum Genomics"},{"key":"10.1016\/j.contraception.2016.03.003_bb0120","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2217\/pgs.11.106","article-title":"Genetic variants in CYP (\u22121A2, \u22122C9, \u22122C19, \u22123A4 and -3A5), VKORC1 and ABCB1 genes in a black south African population: a window into diversity","volume":"12","author":"Dandara","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.contraception.2016.03.003_bb0125","series-title":"The injectable contraceptive: user, social and pharmacological perspectives","author":"Smit","year":"2003"},{"key":"10.1016\/j.contraception.2016.03.003_bb0130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5694\/j.1326-5377.1981.tb135992.x","article-title":"A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate","volume":"1","author":"Fraser","year":"1981","journal-title":"Med J Aust"},{"key":"10.1016\/j.contraception.2016.03.003_bb0135","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/0960-0760(91)90293-E","article-title":"Long-acting hormonal contraceptives for women","volume":"40","author":"Garza-Flores","year":"1991","journal-title":"J Steroid Biochem Mol Biol"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782416001001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782416001001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:38:10Z","timestamp":1600303090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782416001001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0010782416001001"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2016.03.003","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2016.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}